Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Jun 30;6(3):98.
doi: 10.3390/jof6030098.

Bloodstream Infection by Saccharomyces cerevisiae in Two COVID-19 Patients after Receiving Supplementation of Saccharomyces in the ICU

Ioannis Ventoulis  1 , Theopisti Sarmourli  2 , Pinelopi Amoiridou  1 , Paraskevi Mantzana  3 , Maria Exindari  2 , Georgia Gioula  2 , Timoleon-Achilleas Vyzantiadis  2
Affiliations
Case Reports

Bloodstream Infection by Saccharomyces cerevisiae in Two COVID-19 Patients after Receiving Supplementation of Saccharomyces in the ICU

Ioannis Ventoulis et al. J Fungi (Basel). .

Abstract

Co-infections have an unknown impact on the morbidity and mortality of the new clinical syndrome called coronavirus disease 2019 (COVID-19). The syndrome is caused by the new pandemic coronavirus SARS-CoV-2 and it is probably connected with severe traces in the elements of the immune system. Apart from possible Aspergillus infections, particularly in patients with acute respiratory distress syndrome (ARDS), other fungal infections could occur, probably more easily, due to the immunological dysregulation and the critical condition of these patients. Probiotic preparations of Saccharomyces are broadly used for the prevention of antibiotic-associated complications, especially in the intensive care units (ICU). On the other hand, Saccharomyces organisms are reported as agents of invasive infection in immunocompromised or critically ill patients. We report two cases of bloodstream infection by Saccharomyces in two patients hospitalised in the ICU, due to severe COVID-19, after Saccharomyces supplementation.

Keywords: COVID-19; Saccharomyces; co-infections; fungaemia.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Guan W.J., Liang W.H., Zhao Y., Liang H.R., Chen Z.S., Li Y.M., Liu X.Q., Chen R.C., Tang C.L., Wang T., et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: A Nationwide Analysis. Eur. Respir. J. 2020;55:2000547. doi: 10.1183/13993003.00547-2020. - DOI - PMC - PubMed
    1. Gangneux J.P., Bougnoux M.E., Cornet M., Zahar J.R. Invasive fungal disease during COVID-19: We should be prepared. J. Mycol. Med. 2020;30:100971. doi: 10.1016/j.mycmed.2020.100971. - DOI - PMC - PubMed
    1. European Centre for Disease Prevention and Control . Influenza-Associated Invasive Pulmonary Aspergillosis, Europe—30 November 2018. ECDC; Stockh, Sweden: 2018.
    1. Koehler P., Bassetti M., Kochanek M., Shimabukuro-Vornhagen A., Cornely O.A. Intensive Care Management of Influenza-Associated Pulmonary Aspergillosis. Clin. Microbiol. Infect. 2019;25:1501–1509. doi: 10.1016/j.cmi.2019.04.031. - DOI - PubMed
    1. Yang X., Yu Y., Xu J., Shu H., Xia J., Liu H., Wu Y., Zhang L., Yu Z., Fang M., et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single centered, retrospective, observational study. Lancet Respir. Med. 2020;8:475–481. doi: 10.1016/S2213-2600(20)30079-5. - DOI - PMC - PubMed

Publication types

LinkOut - more resources